This broader context was a central part of Martin Toscano\u2019s contribution to the webinar; Mexico combines a substantial manufacturing base, geographic proximity to the United States and preferential access through the USMCA. The country has developed industrial capabilities across automotive, aerospace, chemicals, consumer goods, healthcare and other manufacturing sectors. More than 70% of Mexican exports are destined for the U.S. market, illustrating the depth of Mexico\u2019s integration into North American supply chains.<\/p>\n
This position has become increasingly relevant as companies regionalize supply chains. Yet the opportunity is accompanied by uncertainty.<\/p>\n
Toscano emphasized that geopolitical volatility, tariffs and changing trade conditions are becoming important investment variables. He also identified energy, water, infrastructure, regulation and local value-chain integration as constraints that could limit Mexico\u2019s ability to fully benefit from regionalization.<\/p>\n
These concerns are consistent with Mexico\u2019s wider economic environment. The U.S. decision in July 2026 not to proceed with a planned USMCA extension increased planning uncertainty, although the agreement itself remains in force (Office of the United States Trade Representative.<\/p>\n
At the same time, foreign investment remains substantial. Mexico attracted USD 34.97 billion in FDI during the first half of 2026, although 88.5% consisted of reinvested earnings and only 7.8% represented new investments.<\/p>\n
For pharmaceutical and healthcare companies, market potential therefore cannot be considered separately from Mexico\u2019s wider investment environment.<\/p>\n<\/div>
<\/div><\/div><\/div><\/div><\/div>
Access and regulation remain critical challenges<\/strong><\/h4><\/div>Mexico\u2019s healthcare system continues to face structural limitations. International companies need to balance the complexity and the long-term potential of the market.<\/p>\n
As presented by Eduardo Franky, the 2025\u20132030 Health Sector Program contains ambitious objectives relating to universal healthcare access and regulatory reform. However, budget limitations, fragmented procurement structures and uneven implementation continue to constrain access to innovation.<\/p>\n
Regulatory and market-access barriers remain relevant for foreign companies as well. Germany Trade & Invest identifies lengthy approval procedures and disruptions in public procurement among the risks facing pharmaceutical and medical-technology suppliers in Mexico.<\/p>\n
The webinar also highlighted the scale of the access gap. According to the data presented by Pathway Healthcare Strategy & Consulting, average public access to new medicines in Mexico occurs approximately 5.7 years later than comparable U.S. or European access, while per-capita medicine consumption remains substantially below the OECD average.<\/p>\n<\/div>
<\/div><\/div><\/div><\/div><\/div>
Medical technology adds another growth dimension<\/strong><\/h4><\/div>Beyond pharma, Mexico\u2019s medical-technology market is also expanding. BMI forecasts cited by Germany Trade & Invest indicate that the market could grow from approximately USD 9.3 billion in 2024 to USD 12.4 billion by 2029. Around 81.5% of demand was supplied through imports in 2024, underlining the importance of international suppliers.<\/p>\n
New hospital projects create additional demand for diagnostics, operating-room equipment, sterilization technology and other specialized healthcare infrastructure. This adds another dimension to the opportunity for German technology providers.<\/p>\n<\/div>
<\/div><\/div><\/div><\/div><\/div>
An increasingly relevant sector for German Centre Mexico<\/strong><\/h4><\/div>Healthcare and life sciences are strategically important for German Centre Mexico, both because the sector is strongly represented in our business community and because it reflects the German Centre\u2019s role in supporting international companies in key growth markets. The webinar also drew directly on our wider network: Martin Toscano, President of Evonik Mexico and AHK Mexico, is closely connected to German Centre Mexico through CAMEXA and regularly exchanges views with German Centre and LBBW, while Eduardo Franky is an established expert who has already supported companies within the network; Evonik\u2019s presence as a customer at German Centre Singapore further underlines these cross-network ties.<\/p>\n
The German Centre\u2019s role extends beyond office space. It provides an environment in which international companies can establish and develop their Mexican operations while becoming part of an established German-Mexican business network.<\/p>\n
For German companies, the potential extends across the value chain: pharmaceuticals, medical devices, laboratory equipment, packaging, automation, production technology and specialized services.<\/p>\n
Mexico\u2019s healthcare market is expanding, but its significance goes beyond market growth alone. Production is becoming more localized, innovation is gaining importance and the interaction between industrial policy, market access and supply-chain strategy is becoming increasingly relevant.<\/p>\n<\/div>
<\/div>
References<\/strong><\/p>\nGTAI (2026a, April 8). Mexikos Pharmamarkt trotz Regulierung dynamisch<\/em>. Germany Trade & Invest.<\/p>\nGTAI (2026b, March 5). Mexiko nicht nur als Absatzmarkt von Medizintechnik interessant<\/em>. Germany Trade & Invest.<\/p>\nLisker, B. (2026, May 29). Mexiko: Sorge um das Erfolgsmodell<\/em>. Germany Trade & Invest.<\/p>\nMorales, R. (2026, August 24). M\u00e9xico capta un r\u00e9cord de 34,968 millones de d\u00f3lares de IED en el primer semestre de 2026<\/em>. El Economista<\/em>.<\/p>\nOffice of the United States Trade Representative. (2026, July 1). Ambassador Greer issues statement on the USMCA joint review<\/em>.<\/p>\nWebinar source:<\/strong> German Centre Mexico. (2026, September 22). Check-in: Healthcare & Pharma in Mexico<\/em> [Webinar]. Presentations by Martin Toscano, Evonik Industries de M\u00e9xico, and Eduardo Franky, Pathway Healthcare Strategy & Consulting; moderated by Jimena Kreusler.<\/p>\n<\/div><\/div><\/div><\/div><\/div>Similar Posts<\/h5><\/div>More News and Events<\/h6><\/div>
![\"Chinas](\"https:\/\/www.germancentre.com\/wp-content\/uploads\/2023\/03\/chinas-medtech-market-event.jpg\" "\\"chinas-medtech-market-event\\"")
<\/span><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>